Management of cardiovascular complications of bruton tyrosine kinase inhibitors.

导出 LinkOut

翻译打印收藏纠错

第一作者： Chloe Pek Sang,Tang

第一单位： Oxford University Hospitals NHS Trust, Oxford, UK.

作者： Chloe Pek Sang,Tang ^[1] ; Gregory Y H,Lip ^[2] ; Terry,McCormack ^[3] ; Alexander R,Lyon ^[4] ; Peter,Hillmen ^[5] ; Sunil,Iyengar ^[6] ; Nicolas,Martinez-Calle ^[7] ; Nilima,Parry-Jones ^[8] ; Piers E M,Patten ^[9] ; Anna,Schuh ^[10] ; Renata,Walewska ^[1] ; BSH guidelines committee, UK CLL Forum ^[11]

作者单位： Oxford University Hospitals NHS Trust, Oxford, UK. ^[1] Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK. ^[2] Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. ^[3] Hull York Medical School, Hull, UK. ^[4] Royal Brompton NHS Trust, London, UK. ^[5] Leeds Teaching Hospital NHS Trust, Leeds, UK. ^[6] Royal Marsden Hospital NHS Trust, Sutton, UK. ^[7] Nottingham University Hospitals NHS Trust, Nottingham, UK. ^[8] Aneurin Bevan University Health Board, Abergavenny, UK. ^[9] Comprehensive Cancer Centre, Kings College London, London, UK. ^[10] University Hospitals Dorset NHS Trust, Poole, UK. ^[11]

关键词 atrial fibrillation bruton tyrosine kinase inhibitor cardiovascular complication hypertension ibrutinib sudden cardiac death